You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
NSAID that preferentially inhibits COX-1 (IC50 values are < 0.03, 1.2 and > 30 μM for COX-1, COX-2 and 5-lipoxygenase respectively). Inhibits formation of pro-inflammatory arachidonic acid metabolites in isolated human peripheral polymorphonuclear leukocytes. Opener of inward rectifying hKir2.3 channel (EC50 = 402 nM).
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 320.75. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.12 mL||15.59 mL||31.18 mL|
|5 mM||0.62 mL||3.12 mL||6.24 mL|
|10 mM||0.31 mL||1.56 mL||3.12 mL|
|50 mM||0.06 mL||0.31 mL||0.62 mL|
References are publications that support the biological activity of the product.
Moilanen et al (1988) CP-66,248, a new anti-inflammatory agent, is a potent inhibitor of leukotriene B4 and prostanoid synthesis in human polymorphonuclear leucocytes in vitro. Eicosanoids 1 35 PMID: 2856170
Kirchner et al (1997) Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J.Pharmacol.Exp.Ther. 282 1094 PMID: 9262379
Liu et al (2002) Tenidap, a novel anti-inflammatory agent, is an opener of the inwardly rectifying K+ channel hKir2.3. Eur.J.Pharmacol. 435 153 PMID: 11821021
If you know of a relevant reference for Tenidap, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Tenidap, Tenidap supplier, NSAID, cyclooxygenase, COX-1, inhibitors, inhibits, KIR23, openers, Cyclooxygenase, Oxygenases, Oxidases, Potassium, KIR, Channels, KATP, Inward, Rectifier, K+, CP66248, CP, 66248, rectifier, 2580, Tocris Bioscience
Citations for Tenidap
Citations are publications that use Tocris products.
Currently there are no citations for Tenidap. Do you know of a great paper that uses Tenidap from Tocris? Please let us know.
Reviews for Tenidap
There are currently no reviews for this product. Be the first to review Tenidap and earn rewards!
Have you used Tenidap?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.